T-cell therapy formulation

Details T-cell therapy formulation T-cell therapy formulation

2008-07-22

2008-07-22

Belyavskyi, Michail A (Department: 1644)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Primate cell, per se

C530S391100

Reexamination Certificate

active

07402431

ABSTRACT:
Ex-vivo prepared T-cells are harvested from cell culture conditions and formulated in medium suitable for infusion. The formulation is made by labeling the cells with one or more agents which have reactivity for T-cell surface moieties capable of delivery activation signals upon cross-linking and mixing the labeled cells with biodegradable nanospheres or microspheres coated with a material capable of cross-linking the agents attached to the T-cell surface moieties. Alternatively, the formulation may be made by mixing a population of T-cells with biodegradable nanospheres or microspheres coated with a first material and one or more second materials. The first material binds the second material and the second material has reactivity for surface moieties on the T-cells and the interaction of the second materials with the T-cells causes the activation of the T-cells. In either method, the mixture of T-cells and biodegradable spheres are suspended in a medium suitable for infusion, and the mixture is packaged in a container.

REFERENCES:
patent: 5806529 (1998-09-01), Reisner et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6534055 (2003-03-01), June et al.
patent: 2002/0115214 (2002-08-01), June et al.
patent: 2002/0127208 (2002-09-01), Waller et al.
patent: 2004/0228848 (2004-11-01), Har-Noy
patent: WO 03/038062 (2002-10-01), None
patent: WO 03024989 (2003-03-01), None
Antin, J. H. et al. (1992). “Cytokine Dysregulation and Acute Graft-Versus-Host Disease.”Blood, vol. 80, No. 12: pp. 2964-2968.
Anderson, P. et al. (1988). “Crosslinking CD3 with CD2 Using Sepharose-Immobilized Antibodies Enhances T Lymphocyte Proliferation.”Cellular Immunology, vol. 115, No. 2: pp. 246-256.
Asselin-Paturel et al. (1998). “Quantitative Analysis of Th1, Th2 and TGF-β1 Cytokine Expression in Tumor, TIL and PBL of Non-Small Cell Lung Cancer Patients.”Int. J. Cancer, vol. 77, No. 1: pp. 7-12.
Bachmann, M. F. et al. (1997). “Distinct Roles for LFA-1 and CD28 During Activation of Naive T Cells: Adhesion Versus Costimulation.”Immunity, vol. 7, No. 4: pp. 549-557.
Banu, N. et al. (1999). “TGF-β1 down-regulates induced expression of both class II MHC and B7-1 on primary murine renal tubular epithelial cells.”Kidney International, vol. 56, No. 3: pp. 985-994.
Baroja, M.L. et al. (1989). “The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) Provides a Helper Signal and Bypasses the Need for Accessory Cells in T Cells Activation with Immobilized Anti-CD3 and Mitogens.”Cellular Immunology, vol. 120, No. 1: pp. 205-217.
Baxevanis, C. N. et al. (2000). “Compromised anti-tumor responses in tumor necrosis factor-α knockout mice.”Eur. J. Immunol., vol. 30, No. 7: pp. 1957-1966.
Belardelli, F. et al. (2002). “Cytokines as a link between innate and adaptive antitumor immunity.”Trends in Immunology, vol. 23, No. 4: pp. 201-208.
Blazar, B. R. et al. (1997). “Recent advances in graft-versus-host disease (GVHD) prevention.”Immunological Reviews, vol. 157: pp. 79-109.
Blazar, B. R. et al. (1998). “Rapamycin Inhibits the Generation of Graft-Versus-Host-Disease- and Graft-Versus-Leukemia-Causing T Cells by Interfering with the Production of Th1 or Th1 Cytotoxic Cytokines.”Journal of Immunology, vol. 160, No. 11: pp. 5355-5365.
Carayol, G. et al. (1997). “Quantitative Analysis of T Helper 1, T Helper 2, and Inflammatory Cytokine Expression in Patients After Allogeneic Bone Narrow Transplantation: Relationship with the Occurrence of Acute Graft-Versus-Host Disease.”Transplantation, vol. 63, No. 9: pp. 1307-1313.
Carpentier, A. F., G. Auf, et al. (2003). “CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma.”Front Biosci8: E115-27.
Chambers, C. A. et al. (1999). “Costimulatory regulation of T cell function.”Current Opinion in Cell Biology, vol. 11, No. 2: pp. 203-210.
Champlin, R., I. Khouri, et al. (1999). “Allogenic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.”Hematol Oncol Clin North Am13(5): 1041-57, vii-viii.
Champlin, R., K. van Besien, et al. (2000). “Allogenic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens.”Curr Oncol Rep2(2): 182-91.
Chang, J. W., M. Peng, et al. (2000). “Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies.”Anticancer Res20(3A): 1329-36.
Chen, Q. et al. (1994). “Production of IL-10 by Melanoma Cells: Examination of its Role in Immunosuppression Mediated by Melanoma.”Int. J. Cancer, vol. 56, No. 5: pp. 755-760.
Childs, R. et al. (2002). “Nonmyeloablative Stem Cell Transplantation for Solid Tumors: Expanding the Application of Allogenic Immunotherapy.”Seminars in Hematology, vol. 39, No. 1: pp. 63-71.
Childs, R. et al. (2000). “Regression of metastatic renal-cell carcinoma after nonmyeloablative allogenic peripheral-blood stem-cell transplantation,”The New England Journal of Medicine, vol. 343, No. 11: pp. 750-758.
Childs, R. W. (2000). “Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases.”Cancer J6(3): 179-87.
Childs, R. W. (2002). “Immunotherapy for solid tumors: nonmyeloablative allogeneic stem cell transplantation.”MedGenMed4(3): 13.
Clerici, M. et al. (1993). “A TH1—>TH2 switch is a critical step in the etiology of HIV infection.”Immunology Today, vol. 14, No. 3: pp. 107-111.
Cohen, P. A., L. Peng, et al. (2000). “CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.”Crit Rev Immunol20(1): 17-56.
Damle, N.K. et al. (1989). “Stimulation Via the CD3 and CD28 Molecules Induces Responsiveness to IL-4 in CD4+CD29+CD45R-Memory T Lymphocytes.”The Journal of Immunology, vol. 143, No. 6: pp. 1761-1767.
Das, H., S. Imoto, et al. (2001). “Kinetic analysis of cytokine gene expression in patients with GVHD after donor lymphocyte infustion.”Bone Marrow Transplant27(4): 373-80.
Daubener, W. et al. (1995). “Establishment of T-helper type 1- and T-helper type 2-like humanToxoplasmaantigen-specific T-cell clones.”Immunology, vol. 86, No. 1: pp. 79-84.
Deeths, M. J. et al. (1999). “CD8+ T Cells Become Nonresponsive (Anergic) Following Activation in the Presence of Costimulation.”The Journal of Immunology, vol. 163, No. 1: pp. 102-110.
De Vita, F., M. Orditura, et al. (2000). “Serum interleukin-10 is an independent prognostic factor in advanced solid tumors.”Oncol Rep7(2): 357-61.
de Waal Malefyt, R. et al. (1993). “Direct Effects of IL-10 on Subsets of Human CD4+ T Cell Clones and Resting T Cells. Specific Inhibition of IL-2 Production and Proliferation.”The Journal of Immunology, vol. 150, No. 11: pp. 4754-4765.
D'Orazio, T. J. et al. (1998). “A Novel Role for TGF-β and IL-10 in the Induction of Immune Privilege.”The Journal of Immunology, vol. 160, No. 5: 2089-2098.
Dudley, M. E. et al. (2002). “Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes.”Science, vol. 298, No. 5594: pp. 850-854.
Egeter, O. et al. (2000). “Eradication of Disseminated Lymphomas with CpG-DNA Activated T Helper 1 Cells from Nontransgenic Mice.”Cancer Research, vol. 60, No. 6: 1515-1520.
Eibl, B. et al. (1996). “Evidence for a Graft-Versus-Tumor Effect in a Patient Treated With Marrow Ablative Chemotherapy and Allogeneic Bone Marrow Transplantation for Breast Cancer.”Blood, vol. 88, No. 4: pp. 1501-1508.
Elsasser-Beile, U. et al. (1999). “Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating ly

Affiliated with

Also associated with

Rating

T-cell therapy formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with T-cell therapy formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and T-cell therapy formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2743602